Beyond Air Inc. (XAIR)
0.38
-0.02 (-5.00%)
At close: Jan 28, 2025, 3:06 PM
undefined% (undefined)
| Bid | 0.38 |
| Market Cap | 27.47M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.41 |
| PE Ratio (ttm) | -0.27 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.38 |
| Volume | 382,592 |
| Avg. Volume (20D) | 1,311,130 |
| Open | 0.39 |
| Previous Close | 0.40 |
| Day's Range | 0.38 - 0.40 |
| 52-Week Range | 0.30 - 2.17 |
| Beta | undefined |
About XAIR
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as br...
Industry Medical - Devices
Sector Healthcare
IPO Date Jun 12, 2018
Employees 107
Stock Exchange NASDAQ
Ticker Symbol XAIR
Website https://www.beyondair.net
Analyst Forecast
According to 4 analyst ratings, the average rating for XAIR stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 425.62% from the latest price.
Buy 75.00%
Hold 25.00%
Sell 0.00%
Next Earnings Release
Beyond Air Inc. is scheduled to release its earnings on Feb 10, 2025,
after market closes.
Analysts project revenue of $934.80K, reflecting a 139.08% YoY growth and earnings per share of -0.15, making a -70.00% decrease YoY.
Analysts project revenue of $934.80K, reflecting a 139.08% YoY growth and earnings per share of -0.15, making a -70.00% decrease YoY.
2 months ago
+7.64%
Beyond Air shares are trading higher. The company ...
Unlock content with
Pro Subscription
3 months ago
+10.57%
Beyond Air shares are trading higher after the company announced a partnership with Healthcare Links to expand access to Beyond Air's LungFit PH system.
